Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 2:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,056 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Drug 40 mg: Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects

NCT00549666
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Lurasidone 40 mg, Placebo 40 mg, Ortho Tri-Cyclen
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2011 · Synced Sep 23, 2026, 2:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Comparative Bioavailability Study of Lisinopril Tablets, 40 mg - Effect of Food Study

NCT01380431
View directory record Official record
Conditions
To Determine Bioequivalence Under Fed Conditions
Interventions
Lisinopril
Drug
Lead sponsor
Par Pharmaceutical, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 26, 2011 · Synced Sep 23, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability of Glatiramer Acetate

NCT01874145
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
GA 20 mg/mL, GA 40 mg/mL
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
35
States / cities
Cullman, Alabama • Gilbert, Arizona • Phoenix, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Sep 23, 2026, 2:50 AM EDT
Terminated Phase 1 Interventional

Effects of Propranolol on Responses to Drug-Related Imagery Scripts

NCT00688805
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Propranolol, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 23, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Results available

Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases

NCT00309842
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelofibrosis, MDS, Refractory Anemia, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Non-Hodgkin's Lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes
Interventions
filgrastim, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, umbilical cord blood transplantation, total-body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
2
States / cities
Minneapolis, Minnesota • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 9, 2020 · Synced Sep 23, 2026, 2:50 AM EDT
Active, not recruiting Phase 4 Interventional

Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE

NCT03581877
View directory record Official record
Conditions
Pulmonary Embolism, Pulmonary Hypertension, Thromboembolism, Right Ventricular Dysfunction
Interventions
Alteplase, EKOS
Drug · Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 89 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Bay Shore, New York • Queens, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2024 · Synced Sep 23, 2026, 2:50 AM EDT
Terminated Phase 1 Interventional

A Phase I Study of the Oral Platinum Agent Satraplatin in Combination With Weekly Docetaxel

NCT00313456
View directory record Official record
Conditions
Tumors, Prostate Cancer
Interventions
Satraplatin
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 9, 2012 · Synced Sep 23, 2026, 2:50 AM EDT
Withdrawn Phase 1 Interventional

Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma

NCT04270929
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
FOLFIRI, FOLFIRINOX, TriSalus Infusion System
Drug · Device
Lead sponsor
Roger Williams Medical Center
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 31, 2021 · Synced Sep 23, 2026, 2:50 AM EDT
Completed Phase 1 Interventional Results available

Prescription Medication Interactions

NCT04315181
View directory record Official record
Conditions
Opioid Use, Sedative Use
Interventions
Opioid Agonist, Sedatives
Drug
Lead sponsor
Sharon Walsh
Other
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 19, 2025 · Synced Sep 23, 2026, 2:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics Study of ALO-02 and OxyContin

NCT01557257
View directory record Official record
Conditions
Management of Moderate to Severe Pain
Interventions
ALO-02, Naltrexone block, OxyContin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 27, 2012 · Synced Sep 23, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension

NCT00591253
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan medoxomil, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
60
States / cities
Alabaster, Alabama • Huntsville, Alabama • Tempe, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Sep 23, 2026, 2:50 AM EDT
Terminated Phase 2 Interventional Results available

Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)

NCT03345407
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo ELLIPTA, Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg, Nemiralisib ELLIPTA 500 µg, Nemiralisib ELLIPTA 750 µg, Albuterol (Salbutamol) MDI or nebules, Standard of care therapy
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Mobile, Alabama • Colorado Springs, Colorado • Daytona Beach, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Sep 23, 2026, 2:50 AM EDT
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

Investigating the Analgesic Potential of (2R,6R)-HNK in Acute Pain in Healthy Volunteers

NCT07504601
View directory record Official record
Conditions
Healthy Volunteers
Interventions
(2R,6R)-Hydroxynorketamine, Placebo
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 60 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 23, 2026, 2:50 AM EDT
Completed Phase 3 Interventional Results available

Efficacy Study Of Tofacitinib In Pediatric JIA Population

NCT02592434
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
CP-690,550 (tofacitinib), placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 17 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
55
States / cities
Little Rock, Arkansas • Loma Linda, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2020 · Synced Sep 23, 2026, 2:50 AM EDT
Recruiting Phase 2 Interventional

Cannabidiol as a Treatment for PTSD and PTSD Comorbid With TBI

NCT04550377
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Traumatic Brain Injury
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 70 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 23, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Results available

Orlistat for the Treatment of Type I Hyperlipoproteinemia

NCT02767531
View directory record Official record
Conditions
Hyperlipoproteinemia Type I, Hypertriglyceridemia
Interventions
Orlistat
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
8 Years to 18 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Sep 23, 2026, 2:50 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant

NCT00303667
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
aldesleukin, natural killer cells, cyclophosphamide, fludarabine phosphate, allogeneic hematopoietic stem cell transplantation, total body irradiation, Thymoglobulin, Cyclosporin A
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Sep 23, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Results available

Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia

NCT00357565
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes, Childhood Acute Myeloid Leukemia in Remission, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Previously Treated Myelodysplastic Syndrome, Secondary Myelodysplastic Syndrome, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Excess Blasts, Refractory Anemia, De Novo Myelodysplastic Syndrome, Childhood Myelodysplastic Syndrome
Interventions
filgrastim, busulfan, cyclosporine, fludarabine phosphate, melphalan, mycophenolate mofetil, umbilical cord blood transplantation
Biological · Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 3 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Sep 23, 2026, 2:50 AM EDT
Completed Phase 1 Interventional Results available

Safety and Pharmacokinetics of Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile

NCT01744730
View directory record Official record
Conditions
Bacterial Infections, Obesity
Interventions
Clindamycin
Drug
Lead sponsor
Phillip Brian Smith
Other
Eligibility
2 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Chicago, Illinois • Kansas City, Kansas • Louisville, Kentucky + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Sep 23, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Results available

Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease

NCT01732718
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Nephropathy
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Sep 23, 2026, 2:50 AM EDT
Completed Phase 4 Interventional Results available

Topical Nitroglycerine Treatment for Radial Artery Spasm Prevention

NCT02832115
View directory record Official record
Conditions
Radial Artery Spasm, Angina, Coronary Artery Disease
Interventions
Topical Nitroglycerine, Topical Lidocaine
Drug
Lead sponsor
Aultman Health Foundation
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Sep 23, 2026, 2:50 AM EDT
Not listed Phase 2Phase 3 Interventional

Effect of Esomeprazole 40 mg.Daily for 7 Days on Acid Reflux and Related Arousals During Sleep in Patients With GERD

NCT01089959
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
esomeprazole
Drug
Lead sponsor
Southern Arizona VA Health Care System
Federal
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 18, 2010 · Synced Sep 23, 2026, 2:50 AM EDT
Completed Phase 4 Interventional Results available

Statin Therapy for Ischemic and Nonischemic Cardiomyopathy

NCT00701220
View directory record Official record
Conditions
Cardiovascular Disease, Cardiomyopathy, Heart Disease, Myocardial Disease, Myocardial Ischemia
Interventions
Atorvastatin Calcium
Drug
Lead sponsor
Philip Binkley
Other
Eligibility
18 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Sep 23, 2026, 2:50 AM EDT
Completed Phase 2 Interventional Results available

Study of the Safety and Efficacy of LCZ696 on Arterial Stiffness in Elderly Patients With Hypertension

NCT01692301
View directory record Official record
Conditions
Hypertension
Interventions
LCZ696, Olmesartan, LCZ696 matching placebo, Olmesartan matching placebo, amlodipine, hydrochlorothiazide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
11
States / cities
Clearwater, Florida • Chicago, Illinois • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Sep 23, 2026, 2:50 AM EDT